Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07314346 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
A Phase 1 study, sponsored by Atea Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07314346 is a Phase 1 study that is actively recruiting participants, run by Atea Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT07314346, a Phase 1 study, is actively recruiting participants, sponsored by Atea Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Interventions
- DRUG Buprenorphine/Naloxone + BEM/RZR
- DRUG Methadone +BEM/RZR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07314346
The ClinicalTrials.gov registry entry for NCT07314346 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Buprenorphine/Naloxone + BEM/RZR is the first listed.
NCT07314346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07314346 about?
NCT07314346 is a clinical study titled "Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone". Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
What is the current status of trial NCT07314346?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-01-07. Estimated completion is 2026-06.
What interventions are being tested in trial NCT07314346?
The interventions under investigation include: Buprenorphine/Naloxone + BEM/RZR (DRUG), Methadone +BEM/RZR (DRUG).
Who is sponsoring clinical trial NCT07314346?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.